This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Curis, PharmAthene: Midday Volume Plays

NEW YORK ( TheStreet) -- Several stocks trading near $5 were moving on above-average volume during Friday's session.

Curis (CRIS - Get Report) dropped by 59 cents, or 19.9%, to $2.37 after the drug company priced a registered direct offering of 6.45 million units at a price of $2.52 a unit for gross proceeds of $15.26 million before fees and expenses. Each unit consists of one share of common stock and a warrant to buy 0.25 of a share at an exercise price of $3.55 per share. Volume topped 1.81 million shares, compared to the 50-day average daily volume of 409,000, according to the Nasdaq.

IsoRay (ISR - Get Report) declined by 36 cents, or 22.8%, to $1.22, retracing some of Thursday's 92% rally. On Thursday, after the company announced that a patient with colorectal cancer tolerated the first Cesium-131(Cs-131) implant well and had no evidence of cancer recurrence or any side effects that can be attributed to the implant at the last follow-up visit. Volume topped 1.34 million shares, compared to the three-month average daily volume of 229,000, according to Yahoo! Finance.

Lodgian (LGN) jumped by 67 cents, or 38%, to $2.45 after an affiliate of Lone Star Funds agreed to acquire the hotel operator for $2.50 in an all-cash deal worth $270 million. Volume topped 979,000 shares, compared to the three-month average daily volume of 18,000.

PharmAthene (PIP - Get Report) rallied by 15 cents, or 8.7%, to $1.88 in the absence of any company-specific news Friday. Earlier this month, the biodefense company said that the Biomedical Advance Research and Development Authority, or BARDA, has intentions to negotiate a contract modification for continued development of its recombinant protective rPA anthrax vaccine candidate, SparVax. PharmAthene said that it would submit a proposal to BARDA by Feb. 1 for funding to advance the rPA vaccine program to the stage of a procurement solicitation. Volume topped 1.66 million shares, compared to the three-month average daily volume of 629,000.

-- Written by Robert Holmes in Boston.

Check out all of Friday's high-volume, under-$5 stocks at the Dollar Store

Follow Robert Holmes on Twitter and become a fan of on Facebook.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
CRIS $2.50 0.00%
ISR $1.61 0.00%
PIP $1.62 0.00%
AAPL $126.37 0.00%
FB $83.20 0.00%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs